CDK2 is shown to be dysfunctional in several malignancies, including lung cancer (cyclin A/CDK), melanoma, osteosarcoma and ovarian cancer (cyclin E/CDK2), which is usually due to overexpression of cyclin E and/or cyclin A [9]. Here, CCNA2 is linked to osteosarcoma.